Bioventus   Report issue

For profit Phase 2
Founded: Durham NC United States (2012)

Organization Overview

First Clinical Trial
2021
NCT05100225
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Bioventus LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

ptp-01 (1 trial)

Drugs in Other Trials (1)

Key: Bioventus (0) Acquired (1)

becaplermin (regranex) (1 trial)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2